Skip to main content

Building on early successes

Person living with ALS in a motorized chair and their caregiver smiling

Kristina, living with ALS

Building on early successes

PHOENIX (NCT05021536) is a Phase 3, randomized, placebo-controlled trial in approximately 65 sites across the U.S. and Europe evaluating the safety and efficacy of sodium phenylbutyrate and taurursodiol (also known as ursodoxicoltaurine) in people living with amyotrophic lateral sclerosis (ALS). Recruitment for this trial is closed in the U.S. and ongoing in Europe.

Looking ahead

Learn more about the trial and enrollment information on ClinicalTrials.gov.

Our commitment

At Amylyx, we are relentlessly driven by a commitment to those living with neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create more moments for the neurodegenerative community.

Clinical trials

Our innovative approach to developing transformative therapeutics has far-reaching potential to improve the management of multiple neurodegenerative diseases. Learn more about our clinical trials.

Latest News